Neutralizing GP41 antibodies and their use

Patent metadata

Field	Value
Publication number	US-10047147-B2
Application number	US-201414450773-A
Country	US
Kind code	B2
Filing date	Aug 4, 2014
Priority date	Nov 7, 2011
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

First claim

We claim:

1. A method for producing an antibody that specifically binds to a target antigen, comprising:
sorting a population of memory B cells isolated from a subject into wells of microtiter plate, wherein the memory B cells are not immortalized and at least 90% of the cells in the population of memory B cells are CD19 + IgA − IgD − IgM − B cells;
incubating the memory B cells with an effective amount of IMDM growth medium comprising IL-21, IL-2, and mouse CD40L for 10-15 days to induce expansion of the memory B cells and secretion of antibodies from the expanded cells into the growth medium;
following the incubation, screening supernatant from the wells for specific binding activity for the target antigen, or neutralization of the target antigen, or both;
selecting expanded cells from a well containing supernatant with specifically binding activity for the target antigen;
amplifying nucleic acid molecules encoding heavy and light chain variable regions from the selected cells; and
expressing the heavy and light chain variable regions from the nucleic acid molecules to produce an antibody comprising the heavy and light chain variable regions;
thereby producing the antibody that specifically binds to the target antigen.

2. The method of claim 1 , further comprising:
administering an effective amount of the target antigen to the subject to induce an immune response to the target antigen in the subject; and
isolating the population of memory B cells from the subject to provide the population of memory B cells that is contacted with the effective amount of growth medium comprising IL-21, IL-2, and CD40L.

3. The method of claim 1 , wherein incubating the population of memory B cells with the growth medium comprising CD40L, IL-2, and IL-21 comprises incubating the population of memory B cells with a population of feeder cells that express CD40L.

4. The method of claim 1 , wherein the population of memory B cells is incubated with the growth medium comprising CD40L, IL-2, and IL-21 for 13 days.

5. The method of claim 1 , wherein the subject is a human subject.

6. The method of claim 1 , wherein the target antigen is from a virus, a fungus, a parasite or a bacteria.

7. The method of claim 1 , wherein the target antigen comprises an HIV-1 gp120 protein or HIV-1 gp41 protein, or an antigenic fragment thereof.

8. The method of claim 1 , wherein the target antigen comprises a tumor associated antigen.

9. The method of claim 1 , further comprising isolating the population of memory B cells from the subject that has been exposed to the target antigen to provide the population of memory B cells that is contacted with the effective amount of growth medium comprising IL-21, IL-2, and CD40L.

10. The method of claim 1 , wherein screening supernatant from the wells for specific binding activity for the target antigen comprises an Enzyme-Linked immunosorbant assay (ELISA) or neutralization assay.

11. The method of claim 1 , wherein the memory B cells isolated from the subject are sorted into the wells of the microtiter plate at 4 cells/well.

12. The method of claim 4 , wherein the memory B cells isolated from the subject are sorted into the wells of the microtiter plate at 4 cells/well in a volume of 50 μl of the growth medium.

Assignees

• Us Health
• The United States Of American As Represented By The Sec Dep Of Health And Human Services

Inventors

• Connors Mark
• Huang Jinghe
• Laub Leo
• Mascola John
• Longo Nancy
• Doria-Rose Nicole

Classifications

• A61P31/18

  for HIV · CPC title

• C07K16/114

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K16/1145 Primary

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title